Tenax Therapeutics (TENX) Total Current Liabilities (2011 - 2026)
Tenax Therapeutics recorded quarterly Total Current Liabilities of $8.5 million in Q1 2026, up 18.59% quarter-over-quarter from $7.2 million in Q4 2025, and up 206.58% year-over-year from $2.8 million in Q1 2025.
Tenax Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 206.58% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 206.58% YoY), while the FY2025 annual figure was $7.2 million, up 52.48% from the prior year.
- Total Current Liabilities came in at $8.5 million for Q1 2026 at Tenax Therapeutics, up from $7.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $8.5 million in Q1 2026 to a low of $602214.0 in Q3 2023.
- A 5-year average of $3.0 million and a median of $2.0 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities sank 52.8% in 2022 and surged 325.38% in 2024, its largest moves.
- Tenax Therapeutics' Total Current Liabilities stood at $1.8 million in 2022, then jumped by 94.13% to $3.6 million in 2023, then surged by 30.83% to $4.7 million in 2024, then surged by 52.48% to $7.2 million in 2025, then increased by 18.59% to $8.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $8.5 million, $7.2 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 8.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.49 Mn |
| Dec 31, 2025 | 7.16 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 602,214.00 |
| Jun 30, 2023 | 823,841.00 |
| Mar 31, 2023 | 983,861.00 |
| Dec 31, 2022 | 1.85 Mn |
| Sep 30, 2022 | 689,822.00 |
| Jun 30, 2022 | 1.45 Mn |
| Mar 31, 2022 | 1.98 Mn |
| Dec 31, 2021 | 1.56 Mn |
| Sep 30, 2021 | 1.46 Mn |
| Jun 30, 2021 | 1.18 Mn |
| Mar 31, 2021 | 1.43 Mn |
| Dec 31, 2020 | 2.12 Mn |
| Sep 30, 2020 | 1.38 Mn |
| Jun 30, 2020 | 2.19 Mn |
| Mar 31, 2020 | 2.51 Mn |
| Dec 31, 2019 | 2.53 Mn |
| Sep 30, 2019 | 1.13 Mn |
| Jun 30, 2019 | 938,089.00 |
| Mar 31, 2019 | 1.01 Mn |
| Dec 31, 2018 | 1.57 Mn |
| Sep 30, 2018 | 516,158.00 |
| Jun 30, 2018 | 792,791.00 |
| Mar 31, 2018 | 311,039.00 |
| Dec 31, 2017 | 1.01 Mn |
| Sep 30, 2017 | 838,552.00 |
| Jun 30, 2017 | 2.18 Mn |
| Mar 31, 2017 | 5.04 Mn |
| Dec 31, 2016 | 6.20 Mn |
| Sep 30, 2016 | 5.06 Mn |
| Jun 30, 2016 | 5.28 Mn |
| Dec 31, 2015 | 4.60 Mn |
| Apr 30, 2013 | 1.91 Mn |
| Jan 31, 2013 | 1.99 Mn |
| Oct 31, 2012 | 1.35 Mn |
| Jul 31, 2012 | 4.00 Mn |
| Apr 30, 2012 | 3.13 Mn |
| Jan 31, 2012 | 5.81 Mn |
| Oct 31, 2011 | 2.10 Mn |
| Jul 31, 2011 | 2.27 Mn |
| Apr 30, 2011 | 2.18 Mn |